HSDD
Hypoactive Sexual Desire Disorder. A condition characterized by persistently low sexual desire causing personal distress. PT-141 (bremelanotide, brand name Vyleesi) is the first FDA-approved peptide treatment for HSDD.
Frequently Asked Questions
What is HSDD?
Hypoactive Sexual Desire Disorder. A condition characterized by persistently low sexual desire causing personal distress. PT-141 (bremelanotide, brand name Vyleesi) is the first FDA-approved peptide treatment for HSDD.
Why is HSDD important in peptide research?
Understanding hsdd is important because it represents a health condition where peptide interventions are being actively researched. Knowledge of the underlying pathology helps inform peptide selection and protocol design.